Rockefeller University Press

Skip to Main Content

Table II

Patients and CMV manifestation

		pp65 antigenemia
Group description	No  antigenemia	Asymptomatic	CMV disease
All patients^{^a} (total = 27)	8 (30%)	10 (37%)	9 (33%)
Recipients of CMV⁺ graft  (n = 13)	4 (31%)	6 (46%)	3 (23%)
Oral GCV prophylaxis  (n = 4)	2 (50%)	0 (0%)	2 (50%)

		pp65 antigenemia
Group description	No  antigenemia	Asymptomatic	CMV disease
All patients^{^a} (total = 27)	8 (30%)	10 (37%)	9 (33%)
Recipients of CMV⁺ graft  (n = 13)	4 (31%)	6 (46%)	3 (23%)
Oral GCV prophylaxis  (n = 4)	2 (50%)	0 (0%)	2 (50%)

^a

All patients were CMV-seropositive before transplantation.